We are international
Donate
TEXT SIZE   


Myeloma Minute
July 30, 2015
07.30.15
July 30, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
   

 
This week's question: What does the deletion of Chromosome 17 mean?


Multiple Myeloma Bone Study
 

New Ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events


August 21-22, 2015

IMF Patient & Family Seminar
Los Angeles, California

Saturday, August 29, 2015
3rd Annual Race to Beat Myeloma Oceanport, New Jersey

Saturday, September 19, 2015
Regional Community Workshop (RCW)
Richmond, Virginia

September 23-26, 2015
XV International Myeloma Workshop
Rome, Italy


Watch the IMF Mambo for Myeloma & Support This Challenge

    

x

Is There a Link Between a Genetic Variation and Poor Myeloma Survival Rate?

In his blog this week, IMF Chairman Dr. Brian Durie comments on news about a multi-institutional study that found patients with multiple myeloma with a genetic variation in the gene FOPNL have poorer outcomes than patients without it. “As one might suspect, much further work is needed to substantiate and understand this finding,” he notes, “but this initial report is quite tantalizing.” To read Dr. Durie’s blog, click HERE.

x

FDA Approves Kyprolis for Combination Use in the Treatment of Myeloma


 

Amgen announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Kyprolis® (carfilzomib) for injection in combination with Revlimid® (lenalidomide) and dexamethasone (KRd) as treatment for relapsed multiple myeloma patients who have received one to three prior lines of therapy. The international phase III ASPIRE trial was instrumental in the FDA’s approval decision. This pivotal trial study showed multiple myeloma patients treated with Kyprolis in combination with standard care lived 50 percent longer compared to those who received standard care alone. Read the full story HERE.

x

European Medicines Agency Grants Accelerated Review of Ixazomib


 

The European Medicines Agency (EMA) recently granted Takeda Pharmaceutical Company’s investigational multiple myeloma drug ixazomib an accelerated review. The EMA gives accelerated assessment for drugs that it believes are of major public health interest, or innovation, in order to expedite their market availability to patients. According to “Pharma Times,” over 39,000 new cases of multiple myeloma are diagnosed annually across the European Union, and Takeda’s ixazomib is the first oral proteasome inhibitor to reach phase III trials. Read the full story HERE.

x

Actor-Comedian Kevin Nealon to Headline IMF's 9th Annual Comedy Celebration


 

The IMF is pleased to announce that actor and comedian Kevin Nealon will headline the IMF’s 9th Annual Comedy Celebration on Saturday, October 10. This year’s gala will benefit the Peter Boyle Research Fund and will support the Black Swan Research Initiative, the IMF’s groundbreaking and collaborative project aimed at developing the first definitive cure for myeloma. The Gala will kick off at 6 PM at the Wilshire Ebell Theatre & Club in Los Angeles. Purchase tickets HERE

x

Register for Webinar "Advocacy in August: How to Connect with your Representative at Home"

 

Please join the IMF Advocacy Team on Wednesday, August 5th at 7:00 PM ET, 4:00 PM PT for their webinar, “Advocacy in August: How to Connect with your Representative at Home.” With the Congressional August recess in full swing, this webinar will give you the tools to educate your members of Congress on the issues that matter most to you and the multiple myeloma community. Whether you’re new to advocacy or a veteran, this webinar is not to be missed! The presentation will focus on breaking down the advocacy process, helping you understand the issues, and teaching you how to get the most out of the resources available to you. To register, please click HERE

x

Take IMF's Advocacy Survey on Myeloma and Medicare Coverage

 

The IMF Advocacy Team will be meeting with representatives from the Center for Medicare and Medicaid Services (CMS) next month to discuss their current drug and stem cell transplant coverage policies. To prepare for the meeting, the IMF has created a short 14-question survey regarding your current Medicare coverage and any issues you may have had with it. The IMF asks that you please take the time to complete the survey so we can better understand the issues facing our myeloma community and take those to CMS in August. To take the survey, please click HERE.

x


Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

 related articles